Canonical senolytic tool compound with real clinical pipeline but evidence still maturing
Look, dasatinib is a case where the original compound and the interesting research are almost two different things. As a BCR-ABL/Src kinase inhibitor for CML, it’s a well-understood oncology tool that’s been on the market since 2006. That part of the story is mature. What we’re interested in here is the senolytic application, which is effectively a different compound in terms of what investigators are actually doing with it.
The Kirkland and Tchkonia group at Mayo Clinic is the origin point for the D+Q framing. The 2015 paper in Aging Cell showed that dasatinib preferentially kills senescent fat cell progenitors while leaving healthy cells largely intact, and quercetin covers the epithelial senescent cell population that dasatinib misses. The mechanism isn’t just “it’s cytotoxic”; it’s targeting the pro-survival networks senescent cells depend on: ephrin receptors, BCR-ABL-related kinase activity in mesenchymal lineages, PI3K/AKT signaling. Selective enough to be useful, broad enough to clear the target population.
Clinical translation is moving. There’s a 2019 pilot in idiopathic pulmonary fibrosis (Kirkland, published in EBioMedicine) showing improved physical function measures in a small N. Trials in diabetic kidney disease have shown some early eGFR-related signals. The Alzheimer’s indication is under active investigation across multiple sites. What we dont have yet is a clean phase 3 confirmation; the trials are phase 1/2, mostly single-site, and effect sizes in the early data are modest. The IPF result looks real but hasn’t been replicated at scale.
Where dasatinib earns its keep in a research library is bench utility. If you’re running a senolytic program, this is your reference compound for the mesenchymal compartment. You can’t do credible senolytic biology without it as a comparator. The combination with quercetin is the canonical positive control in the field. That’s indispensable tool value even before you factor in the clinical translation story.
What we like: the mechanism is genuinely interesting, the clinical pipeline is real, and this compound occupies a position no other small molecule currently fills in aging biology. What we don’t like: the evidence base for the senolytic indication is still early, the oncology-derived dosing (even the intermittent 3-days-per-month approach) carries a meaningful adverse effect profile that complicates healthy-aging research design, and the human signal needs considerably more work before anyone should treat this as a resolved story. Compelling for investigators in the senolytic space; not yet a priority for those working adjacent to it.